FDA Approves New Frontline Regimen for Aggressive ALL Ponatinib lands indication in combination with chemo for Philadelphia chromosome-positive cases Mar 22, 2024
Broader Cancer Risk With CAR-T? AI for Physician Burnout; 'Lollipops' ID Oral Cancer News, features, and commentary about cancer-related issues Mar 22, 2024
Long-Term Breast Cancer Risk in Hodgkin Lymphoma Survivors Treated With Doxorubicin Dose-dependent increase regardless of age at treatment or chest radiotherapy Mar 19, 2024
FDA Panel Gives Thumbs Up to Earlier Use of CAR T-Cell Therapy in Multiple Myeloma Cilta-cel, ide-cel win support despite concerns about early mortality risk Mar 16, 2024
FDA Approves First CAR-T for Chronic Lymphocytic Leukemia Lisocabtagene maraleucel (Breyanzi) nabs new indication for relapsed or refractory CLL/SLL Mar 15, 2024
FDA Panel Endorses Imetelstat for MDS-Related Anemia By 12-2 vote, members find improvement in transfusion independence outweighs risk Mar 14, 2024
Early Death Risk Muddies Risk-Benefit Assessment of CAR-T Therapies for Myeloma FDA advisory panel to weigh the evidence for cilta-cel, ide-cel in day-long meeting Mar 14, 2024
Getting Prostate Cancer Drugs Sooner; Limiting Toxic Emissions; FTC Sues 'Charity' News, features, and commentary about cancer-related issues Mar 14, 2024
FDA Staff Cast Doubt on Novel Drug for MDS-Related Anemia Agency asking its advisors if benefits outweigh risks for patients who fail on standard treatment Mar 12, 2024
Sickle Cell Pain Hospitalizations Rose After CDC's Opioid Recs Agency's 2016 guidance may have contributed to reduced access to opioids, and more pain Mar 11, 2024
A Blenrep Comeback? Cancer Vaccine for Dogs; U.K. Snubs Enhertu News, features, and commentary about cancer-related issues Mar 07, 2024
Novel Regimens Yield High Response Rates for Older, Hodgkin Lymphoma Patients Talk of potential cure for some patients with brentuximab plus dacarbazine or nivolumab Mar 06, 2024
IVF Helps Patients Trying to Build Families. An Alabama Court Put That in Doubt "Every month that you're not pregnant feels like grief" Mar 05, 2024
All-Oral AML Regimen Shows Promise for Older, Unfit Patients Response rate of 64% in newly diagnosed patients, 46% in those with refractory/relapsed disease Mar 05, 2024
New Drugs Yield Limited Benefit; Big Jump in Drug Prices; AI Boost for Mammo Results News, features, and commentary about cancer-related issues Mar 01, 2024
PROs for Cutaneous Chronic GVHD After Transplant Tied to Disease Severity, Mortality Baseline QOL, symptom burden could inform risk stratification, treatment decisions Feb 28, 2024
Amy Schumer's Diagnosis; FDA Yanks Cancer Drug; Nursing Student Murdered Health news and commentary from around the Web gathered by 51˶ staff Feb 26, 2024
Transforming Shots Into Pills; 'Tip of the Iceberg' for TILs? Food Additives Warning News, features, and commentary about cancer-related issues Feb 23, 2024
Male Fertility Problems in the Family Linked to Cancer Risk Low sperm levels were tied to specific cancers in family members Feb 22, 2024
Elotuzumab Misses Mark Again as Frontline Treatment for Multiple Myeloma No PFS benefit from adding the monoclonal antibody to standard therapy Feb 20, 2024
For Kids With Sickle Cell Disease Prescribed Opioids, No Patterns of Misuse Emerged Number of vaso-occlusive crises tied to days' supply Feb 19, 2024
Rush to Publish? Medicare Drug Plan Lawsuit Quashed; Activity Curbs Cancer Pain News, features, and commentary about cancer-related issues Feb 16, 2024
Oldest Patient 'Cured' of HIV Still in Remission 5 Years After Transplant for AML But it's unlikely stem cell transplants will ever be large-scale cure for HIV, says expert Feb 14, 2024
FLT3 Inhibitor Highly Active in Newly Diagnosed Acute Myeloid Leukemia Complete response rate of 86%, median event-free survival approaching 4 years with crenolanib Feb 13, 2024
No Relief From Drug Shortages; New Lymphedema Guideline; A 'Good' Patient No More News, features, and commentary about cancer-related issues Feb 09, 2024
Pulled Myeloma Drug May Have a Role in Treating the Disease After All Belantamab mafodotin boosts PFS by nearly 2 years when combined with bortezomib, dexamethasone Feb 07, 2024
All-Oral Therapy Promising in Higher-Risk MDS, CMML In small trial, overall response rate was 95% Feb 05, 2024
Camp Lejeune Water Contamination Tied to a Range of Cancers, CDC Study Says Health risks now more firmly established, but study falls short of being definitive Feb 01, 2024
Most Immunocompromised Patients Clear Omicron Infections B-cell malignancies, B-cell treatments associated with longer duration of infection Jan 30, 2024
When a Revolutionary Cancer Treatment Causes Cancer The potential benefits of CAR T-cell therapies still far outweigh the risks Jan 27, 2024
CAR-T Investigation: FDA Leaders Detail Decision on Cancer Risk Warning Post-treatment cases grow to 22 since products' initial approvals Jan 24, 2024
FDA Calls for New Boxed Warning on All CAR-T Products Most serious warning would alert patients, providers on potential risk for secondary malignancies Jan 23, 2024
Gene Therapy for Sickle Cell Disease Likely Cost-Effective if Under $2 Million Lifetime reduction in acute pain episodes should offset high upfront costs of the therapy Jan 22, 2024
Two Million Cancers; Casgevy OK'd for Thalassemia; Rectal Exams and Prostate Cancer News, features, and commentary about cancer-related issues Jan 19, 2024
Kate Middleton Hospitalized; Sen. Paul Urges Prison for Fauci; COVID Back in Class Health news and commentary from around the Web gathered by 51˶ staff Jan 17, 2024
Carvedilol No Help in Preventing Heart Failure in Childhood Cancer Survivors While safe, the results do not support use of the drug in anthracycline-exposed survivors Jan 10, 2024
Direct Thrombin Inhibitor Shows Benefit for Progressing Stroke Urgent anticoagulation with argatroban shows no bleeding downside in EASE trial Jan 09, 2024
Gene Therapy for Hemophilia Becomes a Reality Uptake of new options for hemophilia A and B has been a bit slow Dec 29, 2023
Chemo-Free Quadruplet Promising as Initial Treatment in DLBCL Approach could allow for a response-adapted reduction of CHOP Dec 27, 2023 video
Longer Letermovir Prophylaxis Reduced Risk of Cytomegalovirus Infection After HSCT Randomized study showed extending prophylaxis from 100 to 200 days was effective and safe Dec 27, 2023
